3/28
08:00 am
crbp
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
Medium
Report
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
3/18
08:08 pm
crbp
BMO Hosts Second Annual Obesity Summit on the Future of the GLP-1+ Market [Yahoo! Finance]
Medium
Report
BMO Hosts Second Annual Obesity Summit on the Future of the GLP-1+ Market [Yahoo! Finance]
3/18
08:44 am
crbp
BMO Hosts Second Annual Obesity Summit on the Future of the GLP-1+ Market [Globe and Mail, The (Toronto, Canada)]
High
Report
BMO Hosts Second Annual Obesity Summit on the Future of the GLP-1+ Market [Globe and Mail, The (Toronto, Canada)]
3/12
12:08 pm
crbp
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $51.00 price target on the stock.
Low
Report
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $51.00 price target on the stock.
3/12
08:05 am
crbp
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock, down previously from $75.00.
Low
Report
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock, down previously from $75.00.
3/11
03:17 pm
crbp
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its price target lowered by analysts at Jefferies Financial Group Inc. from $70.00 to $53.00. They now have a "buy" rating on the stock.
Low
Report
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its price target lowered by analysts at Jefferies Financial Group Inc. from $70.00 to $53.00. They now have a "buy" rating on the stock.
3/11
08:06 am
crbp
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Medium
Report
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
3/11
08:00 am
crbp
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
Low
Report
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
3/6
11:08 pm
crbp
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) was upgraded by analysts at StockNews.com to a "sell" rating.
2/28
07:22 am
crbp
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Low
Report
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
2/25
08:06 am
crbp
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/25
08:00 am
crbp
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Medium
Report
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
2/18
08:00 am
crbp
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Medium
Report
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
2/11
07:30 am
crbp
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
High
Report
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
2/10
08:00 am
crbp
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock, down previously from $80.00.
High
Report
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock, down previously from $80.00.
1/28
08:00 am
crbp
Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference
Low
Report
Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference
1/13
11:04 pm
crbp
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) was upgraded by analysts at StockNews.com to a "sell" rating.
1/8
08:00 am
crbp
Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025
Medium
Report
Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025
1/6
08:00 am
crbp
Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference